Form 4: Catalyst Pharma CSO Reports Equity Grants & Vesting

Catalyst Pharmaceuticals' Chief Strategy Officer, Preethi Sundaram, reported recent stock option grants, RSU vestings, and share disposals for tax purposes.

Summary

• Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported several transactions.
• On November 20, 2025, Sundaram was granted 106,873 options to purchase common stock at an exercise price of $22.77 per share, which will vest in three equal annual tranches starting November 20, 2026, and expire on November 20, 2032.
• Also on November 20, 2025, Sundaram was granted 32,257 Restricted Stock Units (RSUs), vesting in three equal annual tranches starting November 20, 2026.
• On November 21, 2025, 5,603 Restricted Stock Units vested, resulting in the acquisition of 5,603 shares of common stock.
• Concurrently on November 21, 2025, 1,364 shares of common stock were disposed of to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Sundaram directly beneficially owns 45,320 shares of common stock, 785,305 options to purchase common stock, and 811,959 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing reports routine executive compensation transactions (grants, vesting, tax withholding) which are standard and do not indicate a significant positive or negative shift in company performance or outlook.

Positives

• The grant of 106,873 stock options and 32,257 Restricted Stock Units aligns the Chief Strategy Officer's incentives with long-term shareholder value.
• The vesting of 5,603 Restricted Stock Units indicates the achievement of prior compensation milestones.

Future Outlook

NA

Industry Context

This filing details routine executive compensation, which is a standard practice across industries to incentivize management and align their interests with shareholders. It does not provide information on broader industry trends or competitive landscape.

Related Party Transactions

• Grant of 106,873 stock options and 32,257 Restricted Stock Units to Preethi Sundaram, Chief Strategy Officer, as part of executive compensation.
• Vesting of 5,603 Restricted Stock Units and subsequent acquisition of common stock by Preethi Sundaram.
• Disposal of 1,364 shares of common stock by Preethi Sundaram to satisfy tax withholding obligations related to RSU vesting.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Strategy Officer's long-term interests with shareholder value, potentially fostering sustained performance. However, these grants represent a minor potential for future share dilution.
• Employees: The filing reflects standard executive compensation practices within the company, which can influence overall compensation philosophy.

Next Steps

• Future tranches of options and Restricted Stock Units will vest on their respective schedules, with the next vesting dates occurring on November 20, 2026, and November 21, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including grants of stock options and restricted stock units, along with the vesting of previous awards and subsequent share disposals for tax purposes. These transactions are standard and do not provide new fundamental information to warrant a change in investment recommendation. The grants align executive interests with shareholder value over the long term, which is generally positive, but the filing itself does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Executive Compensation, Equity Grant